Daniel A. Norris

Results from a phase 1 study of nusinersen (ISIS-SMN _Rx ) in children with spinal muscular atrophy

Claudia A. Chiriboga, Kathryn J. Swoboda, Basil T. Darras et al. · Neurology · 2016 · 602 citations · Full text

Medicine, Neurology, Pharmacology +14

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Catherine J. Mummery, Anne Börjesson‐Hanson, D. Blackburn et al. · Nature Medicine · 2023 · 318 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates

Frank Rigo, Seung Chun, Daniel A. Norris et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 275 citations · Full text

Medicine, Neuroscience, Pharmacology +14

The effect of physical barriers and properties on the oral absorption of particulates

Daniel A. Norris · Advanced Drug Delivery Reviews · 1998 · 262 citations

Pharmacy, Pharmacokinetics, Oral Drug Delivery +10

Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells

Vijaya D. Makhey, Ailan Guo, Daniel A. Norris et al. · Pharmaceutical Research · 1998 · 214 citations

Pharmacy, Pharmacokinetics, Pharmacology +16